Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT)

Bone Marrow Transplantation volume 37, pages 249–261 (2006)Cite this article

Abstract

More than 40 000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improvements in transplant technology, larger numbers of transplant recipients survive free of the disease for which they were transplanted. However, there are late complications that can cause substantial morbidity. Many survivors are no longer under the care of transplant centers and many community health-care providers may be unfamiliar with health matters relevant to HCT. The Center for International Blood and Marrow Transplant Research (CIBMTR), European Group for Blood and Marrow Transplantation (EBMT), and American Society for Blood and Marrow Transplantation (ASBMT) have developed these recommendations to offer care providers suggested screening and prevention practices for autologous and allogeneic HCT survivors.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Antin JH . Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med 2002; 347: 36–42.

    Article  Google Scholar 

  2. Wingard JR, Vogelsang GB, Deeg HJ . Stem cell transplantation: supportive care and long term complications. Hematology 2002. American Society of Hematology Program Book, pp 422–444.

  3. Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group long-term follow-up guidelines from Children's Oncology Group late effects committee and nursing discipline. J Clin Oncol 2004; 22: 4979–4990.

    Article  Google Scholar 

  4. Brennan BM, Shalet SM . Endocrine late effects after bone marrow transplant. Br J Haematol 2002; 118: 58–66.

    Article  Google Scholar 

  5. Leiper AD . Non-endocrine late complications of bone marrow transplantation in childhood: part I. Br J Haematol 2002; 118: 3–22.

    Article  Google Scholar 

  6. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373–3385.

    Article  CAS  Google Scholar 

  7. Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P et al. Prevention of bacterial endocarditis: recommendations of the American heart association. Circulation 1997; 96: 358.

    Article  CAS  Google Scholar 

  8. Ljungman P . Immunization of transplant recipients. Bone Marrow Transplant 1999; 23: 635–636.

    Article  CAS  Google Scholar 

  9. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49: 1–128 (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm).

Download references

Acknowledgements

The authors wish to thank Karina Danner Koptik, RN for her helpful critique of the recommendations, and Robilyn Lake and Sandy Sobotka for their assistance in manuscript preparation. CIBMTR is supported by Public Health Service Grant U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute; K23-CA-82350 from the National Institutes of Health, the National Cancer Institute Agency for Healthcare Research and Quality; Office of Naval Research; Health Resources Services Administration (DHHS); and grants from AABB, Aetna; AIG Medical Excess; American Red Cross; Amgen Inc.; Anonymous donation to the Medical College of Wisconsin; AnorMED Inc.; Berlex Laboratories Inc.; Biogen IDEC Inc.; Blue Cross and Blue Shield Association; BRT Laboratories Inc.; Celgene Corp.; Cell Therapeutics Inc.; CelMed Biosciences; Cubist Pharmaceuticals; Dynal Biotech, LLC; Edwards Lifesciences RMI; Endo Pharmaceuticals Inc.; Enzon Pharmaceuticals Inc.; ESP Pharma; Fujisawa Healthcare Inc.; Gambro BCT Inc.; Genzyme Corporation; GlaxoSmith Kline Inc.; Histogenetics Inc.; Human Genome Sciences; ILEX Oncology Inc.; Kirin Brewery Company; Ligand Pharmaceuticals Inc.; Merck & Company; Millennium Pharmaceuticals; Miller Pharmacal Group; Milliman USA Inc.; Miltenyi Biotec; National Center for Biotechnology Information; National Leukemia Research Association; National Marrow Donor Program; NeoRx Corporation; Novartis Pharmaceuticals Inc.; Novo Nordisk Pharmaceuticals; Ortho Biotech Inc.; Osiris Therapeutics Inc.; Pall Medical; Pfizer Inc.; Pharmion Corp.; QOL Medical; Roche Laboratories; StemCyte Inc.; Stemco Biomedical; StemSoft Software Inc.; SuperGen Inc.; Sysmex; The Marrow Foundation; THERAKOS, a Johnson & Johnson Co.; University of Colorado Cord Blood Bank; Valeant Pharmaceuticals; ViaCell Inc.; ViraCor Laboratories; WB Saunders Mosby Churchill; and Wellpoint Health Network. EBMT Sponsors include: Amgen Europe; Chugai-Aventis; F Hoffman-LaRoche Ltd; Fresenius Biotech GmbH; Gambro BCT; GE Healthcare; Genzyme; Gilead Sciences UK; Miltenyi Biotec GmbH; Pierre Fabre; Pfizer; Schering AG; and Therakos.

Author information

Authors and Affiliations

  1. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA

    J D Rizzo

  2. University of Florida College of Medicine, Gainesville, FL, USA

    J R Wingard

  3. Kantonsspital, Basel, Switzerland

    A Tichelli

  4. Dana-Farber Cancer Institute, Boston, MA, USA

    S J Lee

  5. San Martino Hospital, Genova, Italy

    M T Van Lint

  6. University of Minnesota, Minneapolis, MN, USA

    L J Burns

  7. Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

    S M Davies

  8. University of Michigan, Ann Arbor, MI, USA

    J L M Ferrara

  9. Hôpital St Louis, Paris, France

    G Socié

Authors
  1. J D Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J R Wingard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Tichelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M T Van Lint
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L J Burns
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S M Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J L M Ferrara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Socié
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Socié.

Additional information

This article is being published concurrently in Biology of Blood and Marrow Transplantation, 12 000–000. The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

Appendix A. Self-report screening instruments used for identification of psychosocial distress in cancer patients

Appendix A. Self-report screening instruments used for identification of psychosocial distress in cancer patients

Psychosocial instrument references

  1. 1

    Zabora JR. Screening procedures for psychosocial distress. In: Holland JC, Breitbart W, Jacobsen PB, et al (eds). Psycho-Oncology. Oxford University Press: New York, NY, 1998, pp 653–661.

  2. 2

    Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983; 13:595–605.

  3. 3

    Kugaya A, Akechi T, Okuyama T, Nakano T, Mikami I, Okamura H et al. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 2000; 88:2817–2823.

  4. 4

    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361–370.

  5. 5

    Love AW, Kissane DW, Bloch S, Clarke D. Diagnostic efficiency of the Hospital Anxiety and Depression Scale in women with early stage breast cancer. Aust NZ J Psychiatry 2002; 36:246–250.

  6. 6

    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11:570–579.

  7. 7

    McNair DM, Lorr M, Droppleman LF. Profile of Mood States Manual. Educational and Industrial Testing Service: San Diego, CA, 1992.

  8. 8

    Dugan W, McDonald MV, Passik SD, Rosenfeld BD, Theobald D, Edgerton S. Use of the Zung Self-Rating Depression Scale in cancer patients: feasibility as a screening tool. Psychooncology 1998; 7:483–493.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rizzo, J., Wingard, J., Tichelli, A. et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 37, 249–261 (2006). https://doi.org/10.1038/sj.bmt.1705243

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705243

Keywords

This article is cited by

Search

Advanced search

Quick links